今日盘中，康希诺生物（06185）股价大涨5.01%，引发市场关注。截至发稿时，该股报价46.20港元，成交额达3674.50万港元。
康希诺生物最新发布的2025年第三季度财报显示，公司业绩大幅改善。第三季度实现营业收入3.10亿元，同比增长17.67%；归属于上市公司股东的净利润2792.56万元，同比增长高达842.01%。前三季度累计实现营业收入6.93亿元，同比增长22.13%；归属于上市公司股东的净利润1444.01万元，实现扭亏为盈。
公司表示，第三季度业绩的强劲增长主要源于核心产品曼海欣的出色市场表现。作为中国流脑疫苗领域仅有的四价流脑结合疫苗产品，曼海欣凭借其创新优势，展现出强劲的市场竞争力，市场占有率不断攀升。这一核心产品的优异表现推动了公司前三季度营收同比增长22.13%，成为公司业绩增长的主要驱动力。投资者对康希诺生物的业绩改善表示认可，推动股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.